[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PL2647637T3 - Pochodna purynylopirydynyloamino-2,4-dlfluorofenylo-sulfonamidu, jej farmaceutycznie dopuszczalna sól, sposób jej wytwarzania oraz zawierająca ją jako składnik aktywny kompozycja farmaceutyczna o aktywności hamującej kinazę Raf - Google Patents

Pochodna purynylopirydynyloamino-2,4-dlfluorofenylo-sulfonamidu, jej farmaceutycznie dopuszczalna sól, sposób jej wytwarzania oraz zawierająca ją jako składnik aktywny kompozycja farmaceutyczna o aktywności hamującej kinazę Raf

Info

Publication number
PL2647637T3
PL2647637T3 PL11844745T PL11844745T PL2647637T3 PL 2647637 T3 PL2647637 T3 PL 2647637T3 PL 11844745 T PL11844745 T PL 11844745T PL 11844745 T PL11844745 T PL 11844745T PL 2647637 T3 PL2647637 T3 PL 2647637T3
Authority
PL
Poland
Prior art keywords
purinylpyridinylamino
preparation
pharmaceutically acceptable
pharmaceutical composition
acceptable salt
Prior art date
Application number
PL11844745T
Other languages
English (en)
Inventor
Eun Kyong Shim
Nam Doo Kim
Tae Bo Shim
Seung Yong Kim
Original Assignee
Medpacto Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medpacto Inc filed Critical Medpacto Inc
Publication of PL2647637T3 publication Critical patent/PL2647637T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
PL11844745T 2010-12-02 2011-11-25 Pochodna purynylopirydynyloamino-2,4-dlfluorofenylo-sulfonamidu, jej farmaceutycznie dopuszczalna sól, sposób jej wytwarzania oraz zawierająca ją jako składnik aktywny kompozycja farmaceutyczna o aktywności hamującej kinazę Raf PL2647637T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20100122047 2010-12-02
KR1020110124360A KR101364658B1 (ko) 2010-12-02 2011-11-25 신규한 퓨리닐피리디닐아미노-2,4-디플루오로페닐 설폰아미드 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 Raf키나제의 저해활성을 가지는 약학적 조성물
EP11844745.7A EP2647637B1 (en) 2010-12-02 2011-11-25 Purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative, pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition with inhibitory activity against raf kinase, containing same as active ingredient
PCT/KR2011/009091 WO2012074249A2 (ko) 2010-12-02 2011-11-25 신규한 퓨리닐피리디닐아미노-2,4-디플루오로페닐 설폰아미드 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 Raf키나제의 저해활성을 가지는 약학적 조성물

Publications (1)

Publication Number Publication Date
PL2647637T3 true PL2647637T3 (pl) 2016-06-30

Family

ID=46172371

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11844745T PL2647637T3 (pl) 2010-12-02 2011-11-25 Pochodna purynylopirydynyloamino-2,4-dlfluorofenylo-sulfonamidu, jej farmaceutycznie dopuszczalna sól, sposób jej wytwarzania oraz zawierająca ją jako składnik aktywny kompozycja farmaceutyczna o aktywności hamującej kinazę Raf

Country Status (11)

Country Link
US (1) US9216981B2 (pl)
EP (1) EP2647637B1 (pl)
JP (1) JP5689182B2 (pl)
KR (1) KR101364658B1 (pl)
CN (1) CN103339132B (pl)
AU (1) AU2011337461B2 (pl)
CA (1) CA2820550C (pl)
ES (1) ES2562010T3 (pl)
PL (1) PL2647637T3 (pl)
RU (1) RU2550038C2 (pl)
WO (1) WO2012074249A2 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103102349B (zh) * 2011-11-14 2017-03-15 北京赛林泰医药技术有限公司 蛋白激酶抑制剂及其组合物和用途
US9550781B2 (en) 2011-11-14 2017-01-24 Centaurus Biopharma Co., Ltd. Kinase modulating compounds, compositions containing the same and use thereof
CN103387576A (zh) * 2013-08-09 2013-11-13 中国药科大学 基于嘌呤结构的芳酰胺类Raf激酶抑制剂及其制备方法和用途
TW201726677A (zh) * 2016-01-15 2017-08-01 Centaurus Biopharma Co Ltd 一種調節激酶化合物的對甲苯磺酸鹽及其結晶
US10844062B2 (en) 2016-02-03 2020-11-24 Incheon University Industry Academic Cooperation Foundation Pyridine derivative inhibiting RAF kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof
CA2969295A1 (en) * 2016-06-06 2017-12-06 Pfizer Inc. Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
KR20200055034A (ko) * 2017-09-20 2020-05-20 에이비엠 쎄라퓨틱스 코포레이션 키나아제 억제제로서의 시클릭 이미노피리미딘 유도체
JP7247557B2 (ja) 2018-11-30 2023-03-29 株式会社リコー 回路基板、回路基板の製造方法、撮像装置

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
AU2005245386B2 (en) * 2004-05-07 2008-11-27 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
KR20070119690A (ko) * 2005-03-15 2007-12-20 아이알엠 엘엘씨 단백질 키나제 억제제로서의 화합물 및 조성물
RU2008135690A (ru) 2006-02-06 2010-03-20 Айрм Ллк (Bm) Соединения и композиции в качестве ингибиторов протеинкиназы
EP2170887A2 (en) * 2007-06-07 2010-04-07 Amgen Inc. Heterocyclic compounds as raf kinase modulators
UY32582A (es) * 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
US9550781B2 (en) 2011-11-14 2017-01-24 Centaurus Biopharma Co., Ltd. Kinase modulating compounds, compositions containing the same and use thereof

Also Published As

Publication number Publication date
US20130317023A1 (en) 2013-11-28
CA2820550A1 (en) 2012-06-07
JP2013545768A (ja) 2013-12-26
AU2011337461A1 (en) 2013-07-11
KR101364658B1 (ko) 2014-02-19
JP5689182B2 (ja) 2015-03-25
EP2647637A2 (en) 2013-10-09
CN103339132B (zh) 2017-02-15
ES2562010T3 (es) 2016-03-02
EP2647637A4 (en) 2013-11-20
US9216981B2 (en) 2015-12-22
KR20120060744A (ko) 2012-06-12
CA2820550C (en) 2016-02-23
EP2647637B1 (en) 2016-02-03
WO2012074249A2 (ko) 2012-06-07
RU2550038C2 (ru) 2015-05-10
CN103339132A (zh) 2013-10-02
WO2012074249A3 (ko) 2012-08-23
RU2013129993A (ru) 2015-01-10
AU2011337461B2 (en) 2015-04-02

Similar Documents

Publication Publication Date Title
PL2647637T3 (pl) Pochodna purynylopirydynyloamino-2,4-dlfluorofenylo-sulfonamidu, jej farmaceutycznie dopuszczalna sól, sposób jej wytwarzania oraz zawierająca ją jako składnik aktywny kompozycja farmaceutyczna o aktywności hamującej kinazę Raf
WO2011093672A3 (en) Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase
EP2522653A4 (en) BIGUANIDE DERIVATIVE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE BIGUANIDE DERIVATIVE AS AN ACTIVE SUBSTANCE
HK1250714A1 (zh) 雜芳基衍生物或其藥學上可接受的鹽、其製備方法以及包含其作為活性成分的用於預防或治療pi3激酶相關疾病的藥物組合物
EP2917180A4 (en) GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE SUBSTANCE
HUE037742T2 (hu) Szubsztituált azolok, vírusellenes aktív adalék, gyógyszerészeti készítmény, az elõállításukat célzó eljárás és alkalmazásuk
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
ZA201304858B (en) Active ingredient combinations comprising pyridylethylbenzamides and other active ingredients
ZA201405673B (en) Arylalkyloxy pyrimidine derivative, pesticide for agricultural and horticultural use containing arylalkyloxy pyrimidine derivative as active ingredient, and use of same
SG11201406141UA (en) Immortalized stem cells and medicinal composition and medicinal preparation comprising product thereof as active ingredient
IL231226A (en) Compounds and preparations as kinase c-kit inhibitors, pharmaceutical preparations containing them and their use in the preparation of medicines for the treatment of diseases
WO2012064973A3 (en) Heterocyclic compounds and uses thereof
WO2013100566A8 (en) Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same
IL231050A0 (en) Pyridines are converted in 4,5,6,7 tetrahydro-1hydrogen-pyrazolo[3,4-si], their use as medicine and medical preparations containing them
KR20180085049A (ko) 아리피프라졸을 유효 성분으로 포함하는 케이크 형상 조성물이 함유된 의료용 기구 및 아리피프라졸을 유효 성분으로 포함하는 케이크 형상 조성물
EP3034082A4 (en) Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
WO2011005052A3 (en) Novel arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same
EP2987786A4 (en) AMIDOPYRIDINOL DERIVATIVE OR PHARMACEUTICAL, SALT AND PHARMACEUTICAL COMPOSITION THEREFOR AS ACTIVE SUBSTANCE
EP2742020A4 (en) N1-CYCLIC AMIN-N5-SUBSTITUTED BIGUANIDE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION THEREWITH
EP2871187A4 (en) NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT
IL225105A (en) Heterocyclic compounds, their process, their pharmaceutical preparations and their use in the preparation of drugs
EP2476420B8 (en) Pharmaceutical composition having antimicrobial and fast-healing activity for external administration, process for preparing same
PT2722322T (pt) Derivado de 1,3-di-oxo-indeno, seu sal farmaceuticamente aceitável ou isómero ótico, seu método de preparação, e composição farmacêutica contendo o mesmo como ingrediente ativo, antiviral
EP2789604A4 (en) DAZEZE DERIVATIVE, PHARMACEUTICAL ACCEPTABLE SALT AND METHOD OF MANUFACTURING THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF